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Cornelis JH van de Velde1 and Peter JK Kuppen1*Abstract
Background: Evasion of immune surveillance and suppression of the immune system are important hallmarks of
tumorigenesis. The goal of this study was to establish distinct patterns that reflect a rectal tumors’ immune-phenotype
and to determine their relation to patient outcome.
Methods: The study population consisted of 495 Stage I-IV non-preoperatively treated rectal cancer patients of which
a tissue micro array (TMA) was available. Sections of this TMA were immunohistochemically stained and quantified for
presence of Foxp3+ cells (Tregs) and tumor expression of HLA Class I and non-classical HLA-E and HLA-G. All markers
were, separate and combined, analyzed for clinical prognostic value.
Results: Expression of HLA class I (DFS HR 0.637 (0.458-0.886), p = 0.013), Foxp3+ infiltration above median (OS HR
0.637 (0.500-0.813), p < 0.001 and DFS HR 0.624 (0.491-0.793), p < 0.001) and expression of HLA-G (DFS HR 0.753
(0.574-0.989), p = 0.042) were related to a better clinical prognosis. When these markers were combined, patients
with 2 or 3 markers associated with poor prognosis (loss of HLA Class I, Foxp3+ below median, and weak HLA-G
expression), showed a significantly worse survival (OS and DFS p < 0.001). This immune-phenotype was an
independent predictor for DFS (HR 1.56 (1.14-2.14), p = 0.019).
Conclusions: In conclusion, rectal tumors showing loss of HLA class I expression, Foxp3+ infiltration below
median and weak HLA-G expression were related to a worse OS and DFS. Combining these immune markers lead
to the creation of tumor immune-phenotypes , which related to patient outcome and were significant independent
clinical prognostic markers in rectal cancer.
Keywords: Rectum, Rectal cancer, Immune surveillance, HLA Class I expression, Foxp3+ regulatory T cells, HLA-E,
HLA-G, OutcomeBackground
The immune system has proven to play an important role
in tumorigenesis and gained a lot of attention in cancer
research [1-4]. Consequently, evasion of immune sur-
veillance has become one of the important hallmarks of
cancer [5]. Tumors are thought to be ‘edited’ through a
Darwinian selection process into poorly immunogenic
tumor variants, invisible to the immune system and able* Correspondence: p.j.k.kuppen@lumc.nl
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unless otherwise stated.to grow progressively. Immuno-editing might influence
patient’s prognosis substantially [6].
We have described a few mechanisms responsible for
evasion of immune surveillance below.
First, cytotoxic T-cells (CTL) are capable of destroying
tumor cells by recognizing tumor-associated antigens
(TAA) on the tumor cell surface presented by classical
human leukocyte antigen (HLA) class I. Tumor cells can
escape this CTL recognition through downregulation or
complete loss of HLA class I, resulting in minimization of
TAA expression and absence of CTL destruction [7-9].
Second, non-classical HLA-E and HLA-G also play an im-
portant role in immune surveillance. Presence of HLA-El Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(NK) cells, resulting in further immune escape [7,10-14].
HLA-E is regularly expressed in various healthy tissues
and correlates with HLA class I expression [15]. HLA-G is
rarely found in healthy tissues, but is frequently observed
in tumors [16]. Third, immune reactivity can become sup-
pressed by the attraction of immunosuppressive regulatory
T cells (Tregs) into the tumor microenvironment [17,18].
In colorectal cancer (CRC), the presence of Tregs in the
tumor micro-environment has been related to a worse
prognosis in some studies, although other studies showed
an inverse association [19-22]. Loss of HLA Class I tumor
expression was related to a better prognosis in CRC in
most studies [14,23] and HLA-E and HLA-G tumor ex-
pression has been correlated with a poor prognosis and
tumor progression [24,25].
In rectal cancer specifically, only a few studies reported
on the role of the immune system, in which expression of
HLA Class I was related to a better prognosis [26,27].
Recently, more studies showed differences in biology be-
tween colon- and rectal cancer [28-30]. Unfortunately,
most studies so far have focused on CRC and did not per-
form separate analyses. Furthermore, often only one im-
mune marker was investigated in CRC, while recent
studies showed the complex interaction between the dif-
ferent mechanisms of immune-escape [6,31,32].
In this study we therefore aimed to investigate the
immune-related biomarkers HLA Class I, HLA-E and -G
and Tregs, determined with immunohistochemistry, in
rectal cancer specifically, and to establish distinct patterns
that reflect immune-escape mechanisms of rectal cancer




The study cohort consisted of patients obtained from
the non-preoperative treated arm of the Dutch TME trial
(January 12th, 1996, DUT-KWF-CKVO-9504, EORTC-
40971, EU-96020), a multicenter trial that evaluated total
mesorectal excision (TME) surgery with or without pre-
operative radiotherapy (5 × 5 Gray) from 1996–1999
[33]. Radiotherapeutical, surgical and pathological proce-
dures were standardized and quality-controlled [34].
Before the start of the TME trial the Medical Ethical
Committee of the Leiden University Medical Center ap-
proved the trial and retrospective use of samples. Writ-
ten informed consent for participation and retrospective
use of samples was obtained from all patients enrolled
in the TME trial. Previously, a tissue microarray (TMA)
including 1208 patients (irradiated and non-irradiated)
of the Dutch TME trial was available. Because of insuffi-
cient tissue on this TMA a new TMA was constructed
for this study. Sufficient formalin-fixed paraffin-embeddedtumor material was available for 495 non-preoperative
radiotherapy-treated stage I-IV Dutch patients, resulting
in a total study cohort of 495 rectal cancer patients who
only had surgery.
Antibodies
The mouse monoclonal antibodies HCA2 and HC10 were
used, which recognize the heavy chains of HLA Class I,
these were kindly provided by Prof. Dr. J. Neefjes (NKI,
Amsterdam, The Netherlands). The reactivity spectrum of
HCA2 comprises all HLA-A chains (except HLA-A24), as
well as some HLA-B, HLA-C, HLA-E, HLA-F, and HLA-
G chains. HC10 reacts with HLA-B and HLA-C heavy
chains and some HLA-A chains (HLA-A10, HLA-A28,
HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33)
[31]. The mouse antibody against human Foxp3 (ab20034
clone 236A/E7; Abcam) was used for Treg identification.
The reactivity spectrum of Foxp3 is composed of regula-
tory T cells and may include small numbers of CD8+ cells
but is generally considered to be the best single marker
for Treg identification [35,36]. For HLA-E and HLA-G
identification mouse monoclonal antibodies against HLA-
E (ab2216 clone MEM-E/02: AbCam) and HLA-G (4H84:
Exbio, Czech Republic) were used [32]. MEM-E/02 recog-
nizes denatured HLA-E [37,38], while 4H84 recognizes
denatured HLA-G molecules and also binds to free heavy
chains of classical HLA class I molecules [38-40].
TMA production and immunohistochemistry
Histo-pathological characteristics of tumor material from
all patients were standardized and quality-controlled
[33,34]. Sections from formalin-fixed paraffin-embedded
(FFPE) tumor blocks of the primary tumors were cut for
haematoxylin and eosin staining. Based on these slides,
histopathologically representative tumor regions were
identified and punched for preparation of tumor tissue
microarray (TMA) blocks. From each donor block, three
1.0 mm diameter tissue cores were punched from three
different identified tumor areas to account for tumor het-
erogeneity and transferred into a receiver paraffin block
using the TMA master (3DHISTECH, Budapest, Hungary).
Immunohistochemical staining (IHC) for Foxp3+ cells,
non-classical HLA-E and HLA-G, and classical HLA class
I tumor expression was performed on 4 μm sections,
which were cut from each receiver block and mounted on
glass. For each type of primary antibodies, all slides were
stained simultaneously to avoid inter-assay variation.
The sections were deparaffinized and rehydrated in ac-
cordance with standard protocol. Endogenous peroxidase
was blocked for 20 minutes in 0.3% hydrogen peroxide in
PBS. For antigen retrieval, slides for staining with HLA-E,
HLA-G or Foxp3+ were boiled in a 0.01 M EDTA buffer
(pH 8) for 10 minutes at maximum power in a micro-
wave oven. Slides for staining with HCA2 and HC10
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were incubated overnight with Foxp3, HLA-E, or HLA-G
antibodies at pre-determined optimal dilution. The next
day, after 30 minutes of incubation with Envision anti-
mouse (K4001; DAKO Cytomation, Glostrup, Denmark),
sections were visualized using diaminobenzidine solution
(DAB). Tissue sections were counterstained with haema-
toxylin, dehydrated and finally mounted in pertex.
For the HCA2 and HC10 stainings a double staining
was performed to better discriminate between stroma
(using a mixture of anti-extracellular matrix antibodies
that resulted in brown staining of tumor stroma) and
tumor tissue (using a blue staining for the HLA expres-
sion to be determined) in the tissue sections. Sections
were incubated overnight at room temperature with all
primary antibodies simultaneously (anti-collagen I, anti-
collagen VI, anti-elastin (all polyclonal rabbit antibodies
obtained from AbCam) and HCA2 and HC10). After-
wards, sections were washed three times for 5 minutes
in PBS and incubated for 30 minutes with Envision + System
HRP anti Rabbit (DAKO, Glostrup, Denmark). After
washing the sections three times with PBS, sections
were developed using Liquid DAB + Substrate Chromo-
gen System (DAKO, Glostrup, Denmark) following
manufacturer’s instructions for visualization of stromal
tissue. Then, sections were washed again three times for
5 minutes in PBS followed by 30 minutes incubation with
rabbit-anti-mouse antibodies (DAKO, Glostrup, Denmark).
Afterwards, the sections were incubated with APAAP
(DAKO, Glostrup, Denmark) diluted in PBS/BSA 1% for
30 minutes. And finally, sections were washed three times
for 5 minutes in PBS followed by 20 minutes incubation
with Vector-Blue following manufacturer’s instructions for
visualization of the HCA2 and HC10 antibodies, and
mounted in Aquamount (Merck, Darmstadt, Germany).
For each patient, normal epithelium, stromal cells, or
lymphoid cells served as internal positive control for
HLA class I and HLA-E antibody reactivity [24]. Tonsil
tissue served as external positive control for the HCA2
and HC10 stainings and placenta tissue slides for the
HLA-E and HLA-G stainings. Slides from human tonsil
tissue served as positive control for Foxp3 staining. Tissue
slides that underwent the whole immuno-histochemical
staining without primary antibodies served as negative
controls (Additional file 1: Figure S1).
Evaluation of immunohistochemistry
Microscopic analysis of HCA2, HC10, HLA-E and HLA-
G expression and presence of Foxp3+ cells was performed
by two independent observers in a blinded manner (M.S.R.:
100% of the cohort, C.C.E. 30% of the cohort). The kappa
values for inter-observer agreement were all between 0.5
and 0.7, indicating substantial agreement between the two
observers [41]. The scores of the three 1.0 mm puncheswere averaged. For HCA2 and HC10 the percentage of
tumor cells with membranous staining was assessed. HLA
class I expression status was determined according to the
International HLA and Immunogenetics Workshop [42],
with tumor cell HLA class I expression status defined as
follows: loss of HLA class I expression: less than 5% of
tumor cells expressing both HCA2 and HC10, downregu-
lation of HLA class I; less than 5% of tumor cells express-
ing either of the markers, and expression of HLA class I:
5% or more expressing both markers. For HLA-E and
HLA-G, intensity of tumor staining (absent (undetectable
or faint in <20% of the cells), weak (faint to weak in 20%
but ≤70% of the cells), moderate (weak to moderate
in >70% of the cells) or strong intensity (intense in 20-70%
of the cells)) was determined, based on previous studies
[43,44]. The scores of the three 1.0 mm punches were av-
eraged as well. For analysis these scores were further cate-
gorized as weak (absent and weak intensity together)
versus strong (moderate and strong intensity together)
tumor staining. Quantification of the number of Foxp3+
cells was microscopically assessed in the entire tumor
punches of the TMA and the absolute number of positive
cells was used for analysis, with the use of the median as
cut-off value for categorization in two categories: Foxp3+
below median and Foxp3+ above median.
Statistical analysis
Statistical analyses were performed using the statistical
package SPSS (version 17.0 for Windows; SPSS Inc.).
The Student’s T-test and the Chi-squared test were used
to evaluate associations between tumor expression of
classical HLA Class I, non-classical HLA-E and HLA-G
and tumor infiltration of Foxp3+ cells and various
clinico-pathological variables. Overall Survival (OS) was
defined as time of surgery until death; Disease Free Sur-
vival (DFS) as time of surgery until death or relapse of
disease, whichever came first. The Kaplan-Meier method
was used for calculation of survival probabilities and the
Log-rank test for comparison of survival curves between
expression levels of markers. Cox regression was used
for univariate and multivariable analysis for OS and
DFS. To preserve statistical power in subgroup analyses,
patients with stage IV disease (n = 32) and positive resec-
tion margin (n = 98) were included in the final analyses.
In multivariable analyses corrections were made for TNM
stage, circumferential margin, age, tumor grade and adju-
vant therapy.
Results
HLA class I tumor expression
The analysis of HLA class I expression was performed
on 468 stage I-IV rectal cancer patients as, due to staining
artifacts and loss of material during the staining proced-
ure, the IHC results of 27 cases could not be analyzed.
Reimers et al. BMC Cancer 2014, 14:486 Page 4 of 12
http://www.biomedcentral.com/1471-2407/14/486Representative images of HLA Class I expression are
shown in Figure 1. Loss of HLA Class I expression was
seen in 70 patients out of 468 patients (15%), down regu-
lation in 105 patients (22%) and expression was present in
the majority of the cases: 293 patients (63%). Patient char-
acteristics and data on HLA class I expression are shown
in Table 1. Patients with loss of HLA class I tumor expres-
sion were diagnosed significantly more often with stage IV
tumors (p = 0.001) and T3 or T4 tumors (p = 0.016). Also,
loss of HLA class I was related to more nodal involvement
(p = 0.003), tumors with poor differentiation (p = 0.033)
and more adjuvant treatment (p = 0.001).
HLA class I expression was borderline significantly re-
lated to a better OS (logrank p-value 0.073), but also sig-
nificantly related to a better DFS (logrank p-value 0.012)
with a HR of 0.637 (95% CI 0.458-0.886, p = 0.013) for
expression of HLA class I compared to loss of HLA class
I expression (Figure 2).
Tumor infiltrating Foxp3+ cells
The number of Foxp3+ cells was evaluated in 478 pa-
tients, as, due to staining artifacts and loss of material dur-
ing the staining procedure, the IHC results of 17 cases
could not be analyzed. Representative images of Foxp3
staining are shown in Figure 1 and patient characteris-
tics and data on Foxp3+ tumor infiltration are shown in
Table 1. The mean number Foxp3+ cells per tumor punchA B
D E
Figure 1 Representative images of HCA2, HC10, HLA-E and –G and
immunohistochemical stainings for HLA Class I expression (HCA2 and H
performed according to standard protocols (details in Material and Met
stromal cells are stained brown); (B) HC10-positive tumor (note: positive tumo
(note: positive tumor cells in brown); (D) HLA-G positive tumor (note: positive
examples of Foxp3+ cells are indicated by arrows) with a magnification in (F)was 39 with a median of 27.0. For further analysis Foxp3+
was categorized as below vs. above median due to skew-
ness in the spread of the data. This resulted in 240 pa-
tients with presence of Foxp3+ cells below median and
238 patients with presence of Foxp3+ cells above me-
dian. Tumors with Foxp3+ cells above median were sig-
nificantly more often stage I tumors (p < 0.001), T1 or T2
tumors (p < 0.001) and showed less nodal involvement
(p = <0.001). Poorly differentiated tumors were associated
with tumors with presence of Foxp3+ cells below median
(p = 0.022). Furthermore, tumors with expression of HLA
class I showed significantly more Foxp3+ cells above me-
dian compared to tumors with loss of HLA class I expres-
sion (p < 0.001).
The presence of Foxp3+ cells above median in the tumor
microenvironment was significantly related to a better OS
(logrank p-value <0.001) and DFS (logrank p-value <0.001)
with HR’s of 0.637 (95% CI 0.500-0.813, p < 0.001) and
0.624 (95% CI 0.491-0.793, p < 0.001) respectively in case
of presence of Foxp3+ cells above median compared to
Foxp3+ cells below median (Figure 3).
HLA-E and HLA-G tumor expression
The analysis of HLA-E and HLA-G was performed on
486 and 484 patients respectively, as, due to staining arti-
facts and loss of material during the staining procedure,
the IHC results of 9 and 11 cases respectively, could notC
F
Foxp3+ staining in rectal cancer. Representative images of
C10), HLA-E and HLA-G expression and presence of Foxp3+ cells,
hods). (A) HCA2-positive tumor (note: positive tumor cells in blue,
r cells in blue, stromal cells are stained brown); (C) HLA-E positive tumor
tumor cells in brown); (E) Presence of Foxp3+ cells (two representative
.
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Male 316 (63.8%) 49 (70.0%) 63 (60.0%) 186 (63.5%) 227 (64.9%) 83 (61.9%) 162 (67.5%) 142 (59.7%)
Female 179 (36.2%) 21 (30%) 42 (40.0%) 107 (36.5%) 123 (35.1%) 51 (38.1%) 78 (32.5%) 96 (40.3%)
Age in years
(mean SD)
64.5 (11.3) 64.8 (12.2) 65.5 (11.0) 64.0 (11.0) 64.7 (11.1) 63.9 (11.7) 64.7 (11.9) (64.2 (10.5)
TNM stage (%)
I 134 (27.1%) 9 (12.9%) 27 (25.7%) 89 (30.4%) 80 (22.9%) 50 (37.3%) 43 (17.9%) 85 (35.7%)
II 136 (27.5%) 19 (27.1%) 25 (23.8%) 90 (30.7%) 98 (28.0%) 37 (27.6%) 65 (27.1%) 71 (29.8%)
III 193 (39.0%) 33 (47.1%) 51 (48.6%) 96 (32.8%) 146 (41.7%) 41 (30.6%) 112 (46.7%) 72 (30.3%)
IV 32 (6.5%) 9 (12.9%) 2 (1.9%) 18 (6.1%) 26 (7.4%) 6 (4.5%) 20 (8.3%) 10 (4.2%)
Tumor grade (%)
Moderate 358 (72.3%) 41 (58.6%) 72 (68.9%) 228 (77.8%) 248 (70.9%) 102(76.1%) 160 (66.7%) 185 (77.7%)
Poor 110 (22.2%) 23 (32.9%) 25 (23.8%) 54 (18.4%) 83 (23.7%) 25 (18.7%) 67 (27.9%) 40 (16.8%)
Well 25 (5.1%) 5 (7.1%) 8 (7.6%) 10 (3.4%) 17 (4.9%) 7 (5.2%) 12 (5.0%) 12 (5.0%)
Missing 2 (0.4%) 1 (1.4%) 1 (0.3%) 2 (0.6%) 1 (0.4%) 1 (0.4%)
Adjuvant therapy
No 402 (81.2%) 46 (65.7%) 84 (80%) 253 (86.3%) 278 (79.4%) 116 (86.6%) 185 (77.1%) 205 (86.1%)
Yes 75 (15.2%) 19 (27.1%) 19 (18.1%) 31 (10.6%) 58 (16.6%) 14 (10.4%) 44 (18.3%) 28 (11.8%)
Missing 18 (3.6%) 5 (7.1%) 2 (1.9%) 9 (3.1%) 14 (4.0%) 4 (3.0%) 11 (4.6%) 5 (2.1%)
Circumferential
margin
Negative 397 (80.2%) 49 (70.0%) 83 (79.0%) 242 (82.6%) 279 (79.7%) 110 (82.1%) 188 (78.3%) 196 (82.4%)
Positive 98 (19.8%) 21 (30.0%) 22 (21.0%) 51 (17.4%) 71 (20.3%) 24 (17.9%) 52 (21.7%) 42 (17.6%)
This table shows the patient characteristics of the entire rectal cancer cohort (n = 495) and stratified for HLA class I, HLA-G and Foxp3+ staining.
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E and HLA-G immunohistochemical staining results are
shown in Figure 1. For HLA-E, 8 patients (1.6%) showed
absence of tumor staining, 73 patients (15.0%) showed
weak tumor staining, 298 patients (61.3%) showed moder-
ate tumor staining and 107 patients (22.0%) showed
strong tumor staining in their punches. For HLA-G, 31
patients (6.4%) had absence of tumor staining, 319 pa-
tients (65.9%) had a weak tumor staining, 103 patients
(21.3%) had a moderate tumor staining and 31 patients
(6.4%) had a strong tumor staining. For analysis the scores
were further categorized as weak (absent and weak inten-
sity together) versus strong (moderate and strong intensity
together) tumor staining. Strong expression was found in
83.3% (405 out of 486) of the tumors for HLA-E and in
27.7% (134 out of 484) of the tumors for HLA-G expres-
sion. Weak expression of HLA-E was significantly related
to T4 tumors (p = 0.020) and more nodal involvement
(p = 0.050). Weak expression of HLA-G was also significantlyrelated to higher tumor stage (p = 0.008) and more
nodal involvement (p = 0.006). Furthermore, strong ex-
pression of HLA-G was significantly associated with
presence of Foxp3+ cells above median (p = 0.001) and
with HLA class I expression (p < 0.001). Strong HLA-E
was also significantly related to HLA class I expression
(p = 0.028).
HLA-E expression was not related to OS (p = 0.823) or
DFS (p = 0.784). Strong expression of HLA-G was border-
line significantly related to a better OS (logrank p-value
0.056) and significantly related to a better DFS (logrank
p-value 0.040) with a HR of 0.753 (95% CI 0.574-0.989,
p = 0.042) in case of strong expression of HLA-G com-
pared to weak expression of HLA-G.
Multivariable analysis
A multivariable analysis was performed for OS and DFS
using the following parameters: age, TNM stage, tumor










Figure 2 Survival curves stratified for HLA class I tumor expression in rectal cancer. A) Kaplan Meier curve for Overall Survival in 495
rectal cancer patients stratified for HLA class I tumor expression status. B) Kaplan Meier curve for Disease Free Survival in 495 rectal cancer
patients stratified for HLA Class I tumor expression. HLA class I was immunohistochemically determined as described in the Material and
Methods section.
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and Foxp3+ tumor infiltration. Foxp3+ was an inde-
pendent significant predictor of OS (p = 0.018) and
DFS (p = 0.012). HLA Class I and HLA-G were not
significantly related to OS and DFS in multivariable ana-
lysis. In Table 2 all univariate and multivariable analyses
are summarized.
Because the type of antibody we used to detect HLA-G
expression is known to bind to free heavy chains of clas-
sical HLA class I molecules as well (38–40), interaction
between these two markers was analysed for survival. In
multivariable analysis for OS there was no interaction
between HLA-G expression and HLA class I expression
(p = 0.174). Also, there was no interaction between
HLA-G expression and the two types of antibodies used
for detection of HLA class I separately; HCA2 expression
(p = 0.183) and HC10 expression (p = 0.461) respectively.
For DFS, there was no interaction between HLA-G ex-
pression and HLA class I expression as well (p = 0.301),
neither for HCA2 (p = 0.516) nor HC10 (p = 0.329).Analysis of tumor immune-phenotypes
The interaction between tumor cells and immune cells
is complex, multifaceted and different interactions are
closely linked to each other. In breast- and colon cancer
patients, immune subtyping has already shown a prom-
ising value in the prediction of prognosis [44,45]. There-
fore, we hypothesized that combined analysis of immune
markers may better reflect patients’ outcome as a result
of interaction between tumor cells and the immune sys-
tem in rectal cancer as well. We have shown above that
patients with tumors showing expression of HLA class I,
expression of HLA-G and presence of Foxp3+ cell infil-
tration above median showed better survival outcomes
when analyzed separately. HLA-E tumor expression was
not related to survival. Based on the prognostic value of
the individual markers, a score was created for the com-
bination of HLA class I, HLA-G and Foxp3+. HLA class
I was divided into 3 scores, which ranged from 0 for loss
of expression to 2 for high expression. HLA-G and








Figure 3 Survival curves stratified for Foxp3+ tumor infiltration in rectal cancer. A) Kaplan Meier curve for Overall Survival in 495 rectal
cancer patients stratified for Foxp3+ tumor infiltration based on the median of the total Foxp3+ infiltration in this cohort. B) Kaplan Meier curve
for Disease Free Survival in 495 rectal cancer patients stratified for Foxp3+ tumor infiltration. Foxp3+ tumor infiltration was immunohistochemically
determined as described in the Material and Methods section.
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expression or Foxp3+ above median. Combining the scores
of the individual markers resulted in a scoring range from 0
to 4. The entire population was divided into 3 tumor
immune-phenotypes: patients with scores 3 and 4 (pheno-
type 1, n = 210), patients with score 2 (phenotype 2, n = 139)
and patients with scores 0 and 1 (phenotype 3, n = 112).
In survival analyses, these phenotypes showed significant
differences in patient outcome. Survival outcome increased
with an increasing number of positive prognostic immune
markers expressed in the tumor. Patients with phenotype 3
showed a significantly worse OS (logrank p < 0.001) and
DFS (logrank p < 0.001) with HR’s of 1.88 (95% CI 1.40-
2.53, p < 0.001) for OS and 2.06 (95% CI 1.54-2.75, p < 0.001)
for DFS, when compared to phenotype 1 (Figure 4).
Multivariable analysis of the tumor immune-phenotypes
For the tumor immune-phenotype, univariate analysis
and multivariable analysis was also performed to determineOS and DFS as written above. In univariate analysis the
immune-phenotype was a significant predictor of OS
(p < 0.001) and DFS (p < 0.001) (Table 2). In multivariable
analysis the immune-phenotype was an independent
predictor of DFS (p = 0.019). It was not an independent
predictor of OS (p = 0.122). When compared to the
multivariable analyses of the individual immune markers
as shown in Table 2, the combination between immune
markers, the tumor immune-phenotype, showed a stron-
ger and additive prognostic potential, indicating a complex
and multifaceted interaction between tumor cells and im-
mune cells.Discussion
In this study, by combining the immune-related tumor
markers HLA class I, HLA-G and Foxp3+, we reported
an independent association between tumor immune-
phenotype and patient outcome. These phenotypes might
Table 2 Univariate and multivariable analyses of Disease Free Survival (DFS) and Overall Survival (OS) for the different
immune markers and for tumor immune phenotypes
DFS OS
Univariate analysis Multivariable analysis** Univariate analysis Multivariable analysis**
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
HLA class I 0.013* 0.548 0.075 0.984
Loss 1.00 1.00 1.00 1.00
Downregulation 0.84 0.58-1.22 1.08 0.72-1.62 0.78 0.53-1.15 1.04 0.68-1.59
Expression 0.64 0.46-0.89 0.91 0.63-1.32 0.68 0.49-0.95 1.03 0.70-1.52
Foxp3+ <0.001* 0.012* <0.001* 0.018*
Below median 1.00 1.00 1.00 1.00
Above median 0.62 0.49-0.79 0.72 0.56-0.93 0.64 0.50-0.81 0.73 0.56-0.95
HLA-G 0.042* 0.849 0.056 0.418
Weak expression 1.00 1.00 1.00 1.00
Strong expression 0.75 0.57-0.99 0.85 0.63-1.13 0.76 0.58-1.01 0.88 0.66-1.19
Immune phenotype <0.001* 0.019* <0.001* 0.122
Phenotype 1 1.00 1.00 1.00 1.00
Phenotype 2 1.26 0.94-1.68 1.13 0.83-1.54 1.18 0.87-1.58 1.07 0.78-1.47
Phenotype 3 2.06 1.54-2.75 1.56 1.14-2.14 1.88 1.40-2.53 1.39 1.01-1.92
TNM stage <0.001* <0.001*
I-II 1.00 1.00
III-IV 2.65 2.09-3.37 2.65 2.08-3.38
Circumferential margin <0.001* <0.001*
Negative 1.00 1.00
Positive 2.26 1.73-2.94 2.42 1.85-3.16
Age (continuous) 1.03 1.02-1.04 <0.001* 1.04 1.03-1.05 <0.001*
Tumor grade 0.094 0.058
Well 1.00 1.00
Moderate 0.88 0.53-1.46 0.87 0.52-1.44
Poor 1.19 0.69-2.04 1.21 0.70-2.09
Adjuvant chemotherapy <0.001* <0.001*
No 1.00 1.00
Yes 2.38 1.77-3.20 2.43 1.80-3.28
*Statistical significance.
**Corrected for TNM stage, circumferential margin, age, tumor grade and adjuvant therapy.
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and metastases in rectal cancer.
Previous studies on HLA class I expression, which fo-
cused on a mixed population of colon- and rectal cancer
together, have shown inconsistent findings [13,14]. Our
study showed a survival benefit for patients with tumors
expressing HLA class I. These results are partly compar-
able with results from Watson et al., who showed that
low expression of HLA class I was related to a poor
prognosis in a large group of colorectal cancer patients,
whereas tumors with loss or expression of HLA class I
were associated with a survival benefit [14]. A substan-
tial part of Watson’s cohort showed HLA class I negativetumors (24.6%). In our cohort, consisting solely of rectal
cancer patients, only 15.0% of the patients had tumors
with loss of HLA class I expression, which might indi-
cate that colon cancers lose their HLA class I expression
more often. Previously, Speetjens et al. investigated the
prognostic value of HLA class I expression in rectal can-
cer patients from the Dutch TME Trial as well [27]. In
this study, as described in the methods sections, a new
TMA was used without complete overlap and thus dif-
ferent patients. Both studies showed a survival benefit
for patients with tumors showing expression of HLA
class I. Because we have changed the scoring criteria










Figure 4 Survival curves stratified for immune-phenotypes in rectal cancer. A) Kaplan Meier curve for Overall Survival in 495 rectal cancer
patients stratified for all the different combinations between tumor expression of HLA class I, HLA-G and the presence of Foxp3+ cells based on
which 3 immune-phenotypes could be distinguished. See results section for explanation of the phenotypes. B) Kaplan Meier curve for Disease
Free Survival in 495 rectal cancer patients stratified for all the different combinations between tumor expression of HLA class I, HLA-G and the
presence of Foxp3+ cells based on which 3 immune phenotypes could be distinguished. See results section for explanation of the phenotypes.
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http://www.biomedcentral.com/1471-2407/14/486and Immunogenetics Workshop [42] differences have to
be acknowledged. Speetjens et al. reported that 16% of
non-irradiated patients had tumors with loss and down-
regulation of HLA Class I, whereas our study showed
37% (15% loss and 22% downregulation). Thus, besides
a different patient cohort, other possible explanations
for inconsistent findings between studies are the use of
different definitions of HLA class I expression and dif-
ferences in staining techniques. Furthermore, tumor
microsatellite status might also play an important role.
Approximately 50% of all proximal colon tumors show
microsatellite instability (MSI), whereas almost all distal
colon and rectal cancers are microsatellite stable (MSS)
tumors [46,47]. Loss of HLA class I has been describedmore significantly in MSI colorectal tumors compared
to MSS right-sided colon tumors [48,49]. HLA class I
negative tumors are therefore more likely to be MSI tu-
mors with a different clinical behavior than MSS colo-
rectal tumors [27]. Since MSI tumors have a better
prognosis, MSI might influence prognostic results when
considering HLA class I expression in colorectal tumors
[46]. In this rectal cancer cohort determination of the
microsatellite status would not have been useful. Re-
search has shown that in only 2% of rectal cancers MSI
can be found [50], resulting in insufficient statistical
power for separate analyses Finally, colon and rectum
are biologically different tissues; the colon epithelium
consists of simple columnar epithelium, whereas the
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to stratified squamous epithelium, which might result in
different outcomes. The Cancer Genome Atlas Network
attempted to find biological differences between colon
and rectal cancer. However, only differences in anatomical
tumor site with more hypermethylation in right-sided tu-
mors were found, which might be explained by different
embryonic origins of the right-and left-sided tumors [28].
Results in our study regarding non-classical HLA-G
are remarkable. HLA-G expression can inhibit NK-cells
from lysing tumor cells that have lost or downregulated
classical HLA class I expression as a secondary immune
escape [51,52]. However, in this study, positive HLA-G
expression was correlated with a longer disease free
survival.
The antibody used to stain HLA-G can also bind to
free heavy chains of classical HLA class I molecules as
well, possibly explaining the remarkable results. We
therefore performed an interaction analysis between
these antibodies. However, no interaction between HLA-
G and HLA class I expression was found. Furthermore,
HLA-G is found to be highly immunosuppressive by dir-
ectly inhibiting NK cells, but also by recruitment of
Tregs and induction of Treg differentiation [53]. Our
study showed that strong HLA-G expression was signifi-
cantly related to presence of more Foxp3+ cells, possibly
explaining the favourable prognosis of tumors with
strong HLA-G expression, since tumors that attracted
more Foxp3+ cells had a better outcome in our cohort.
Immune regulation in cancer still remains complex and
multifaceted, and not all immune related mechanisms
are completely clear. To our knowledge, no other studies
on HLA-E and HLA-G are performed on rectal cancer
specifically and therefore no other comparisons could be
made.
The presence of Foxp3+ cells in the tumor micro-
environment is thought to inhibit host-protective anti-
tumor responses and especially CTL activity [6]. A high
density of tumor infiltrating Foxp3+ cells has shown to
be associated with an unfavorable prognosis in a wide
range of human carcinomas [54,55]. However, in ac-
cordance with our results, opposite results are described
in CRC [20,21]. A possible explanation could be a signifi-
cant association between HLA class I tumor expression
and Foxp3+ tumor infiltration in our cohort. Foxp3+ in-
filtrating cells might be necessary to counteract CTL ac-
tivity in tumors expressing HLA class I to prevent an
auto-immune response on other bodily cells as well. An-
other explanation might be a different micro-environment
of rectal cancer, which is colonized with many gastro-
intestinal bacteria, triggering the production of pro-
inflammatory cytokines causing tumor-enhancing effects.
Instead of the specificity of infiltrating T-cells for tumor-
antigens, T-cells in rectal cancer could be more specificfor the microflora and suppress inflammation and im-
mune responses from bacterial invasion, resulting in an
anti-tumorigenic effect [56].
As shown in our results and results from our previous
studies in breast cancer, immune markers are related to
each other [31,32]. Studying solely one marker might
not be enough to truly understand cancer immune sur-
veillance. When we combined our markers, patients
showing the worst prognosis were patients with tumors
bearing 2 or 3 negative prognostic markers; patients with
loss of HLA class I tumor expression, weak HLA-G
tumor expression and low tumor infiltration with Foxp3+
cells. These patients therefore qualify as very low immune
susceptible. They probably were able to elicit only a min-
imal CTL attack and subsequently attracted little to no
Foxp3+ cells in their tumor micro-environment, possibly
explaining their worse prognosis. Furthermore, patients
with tumors showing loss of HLA class I expression, low
Foxp3+ cell infiltration and strong HLA-G expression
showed the worst outcome perspectives. These patients
probably had tumors which were highly ‘edited’ as well,
causing a minimal CTL attack and subsequently attracted
little to no Foxp3+ cells, and because of strong HLA-G
expression were able to escape further immune recogni-
tion through inhibition of NK cell recognition and subse-
quently no elimination [51,52].
Conclusions
In conclusion, we were able to identify local immune
escape mechanisms of rectal cancer, where the presence
of Foxp3+ infiltration greatly influences a better prognosis.
Loss of HLA class I expression, weak non-classical HLA-
G expression and the presence of Foxp3+ below median
were related to a worse outcome. Combining these immune-
related markers identified 3 groups, which were highly select-
ive and discriminative regarding patient outcome. Prognosis
increased with a decrease in negative prognostic markers.
In the future these findings might contribute to better
treatment allocation.
Additional file
Additional file 1: Figure S1. Representative images of HCA2, HC10,
HLA-E, HLA-G and Foxp3+ staining in rectal cancer. Representative
images of immunohistochemical stainings with positive and negative
controls for HLA Class I expression (HCA2 and HC10), HLA-E and HLA-G
expression and presence of Foxp3+ cells, performed according to standard
protocols (details in Material and Methods section). (A) HCA2 expression,
positive tumor (note: positive tumor cells in blue, stromal cells are stained
brown) (A1), negative tumor (A2), tonsil which served as positive control
(A3), tonsil which underwent the whole immuno-histochemical staining
without primary antibody served as negative control (A4); (B) HC10 expression,
positive tumor (note: positive tumor cells in blue, stromal cells are stained
brown) (B1), negative tumor (B2), tonsil which served as positive control
(B3), tonsil which underwent the whole immuno-histochemical staining
without primary antibody served as negative control (B4); (C) HLA-E expression,
positive tumor (note: positive tumor cells are stained brown) (C1), negative
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http://www.biomedcentral.com/1471-2407/14/486tumor (C2), placenta which served as positive control (C3), placenta which
underwent the whole immuno-histochemical staining without primary
antibody served as negative control (C4); (D) HLA-G expression, positive
tumor (note: positive tumor cells are stained brown) (D1), negative tumor
(D2), placenta which served as positive control (D3), placenta which
underwent the whole immuno-histochemical staining without primary
antibody served as negative control (D4); (E) Presence of Foxp3+ cells,
tumor with presence of Foxp3+ cells (indicated by arrows) (E1), tumor with
absence of Foxp3+ cells (E2), tonsil which served as positive control for
Foxp3+ cells (indicated by arrows) (E3), tonsil which underwent the whole
immuno-histochemical staining without primary antibody served as
negative control (E4).
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